OraSure Technologies Inc (OSUR) - Forward P/S Multiple

The forward P/S trend reflects market expectations for OraSure Technologies (OSUR), with the latest reading standing at 2.10. Valuation growth is driven by partnerships with the public sector and clinics to implement rapid diagnostics. Management is expanding home testing and biomaterial collection methods. Stability is supported by high plant utilization and the planned automation of reagent filling lines, which minimizes technical risks.

OSUR OraSure Technologies, Inc.: Market Cap to Expected Sales Ratio in the range 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for OraSure Technologies (OSUR)

- market price and analyst price targets:

Price Chart OraSure Technologies Inc|OSUR - Fair Value Consensus

- market capitalization indicators:

Market Capitalization OraSure|OSUR - Enterprise Value

- issuer book value statistics:

Net Assets per Single Share OraSure|OSUR - Book Valuation of Business|Market Cap to Net Assets Ratio orasure.com|OSUR - Company Total Assets

- issuer credit burden and liquidity indicators:

- business earnings and investment ratios data:

OSUR - Company Net Income|Projected Future Earnings OraSure Technologies|OSUR - Price to Earnings Ratio|Forward P/E Multiple OraSure Technologies|OSUR - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization OraSure Technologies Inc|OSUR - Operating profit before amortization|Earnings per share for the last twelve months OraSure|OSUR - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months orasure.com|OSUR - Earnings per share growth in current year|Net earnings per share growth forecast for next year OraSure Technologies

- sales volume and revenue indicators:

OSUR - Company Total Revenue|Projected Sales Volume OraSure Technologies, Inc.|OSUR - Price-to-Revenue Multiple|Forward P/S Multiple OraSure Technologies Inc

Initial company analysis:OraSure Technologies Inc (OSUR)

OraSure Technologies (OSUR) possesses strong pricing power in the rapid testing segment, allowing the market to bake a high premium into the forward P/S metric. This chart reflects the ratio of current market capitalization to expected annual revenue, enabling investors to quickly assess shifts in market expectations following new guidance and determine the balance between growth potential and the risk of asset overvaluation.

Key competitors

Forward P/S Multiple A (agilent.com)|Quest Corp (DGX) - Market Cap to Future Revenue Ratio|ILMN - Price-to-Projected Revenue Ratio|EXAS - Forward P/S Multiple|RVTY (Revvity) - Forward Price-to-Revenue Multiple|Bio-Rad - Forward Price to Sales|Price-to-Projected Revenue Ratio anbio.com|Forward P/S Multiple Sotera Health Company|Price-to-Projected Revenue Ratio QuidelOrtho (QDEL)|OPK - Market Cap to Future Revenue Ratio|caredx.com - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Maravai LifeSciences Corp (MRVI)|FLGT: Forward Price-to-Revenue Multiple|Forward Price to Sales LAB (Fluidigm)|Cytek Biosciences Inc (CTKB) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Exagen Inc.|Forward Price-to-Revenue Multiple MDXH|LUCD - Projected Price to Revenue|Price-to-Projected Revenue Ratio Prenetics (PRE)|Price-to-Projected Revenue Ratio IMDX (Insight Molecular Diagnostics Inc)|Trinity Biotech - Forward Price-to-Revenue Multiple|prophaselabs.com - Price-to-Projected Revenue Ratio|AIMD - Price-to-Projected Revenue Ratio|Co-Diagnostics Inc (CODX) - Forward Price-to-Revenue Multiple|HSCS: Forward P/S Multiple|BMRA - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CDIO|Market Cap to Future Revenue Ratio onconetix.gcs-web.com ONCO|Price-to-Projected Revenue Ratio Virax Biolabs (VRAX)|Price to Expected Revenue Ratio BJDX|Price-to-Projected Revenue Ratio Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Market Cap to Future Revenue Ratio|centogene.com - Forward P/S Multiple|ENZ (Enzo Biochem Inc.) - Market Cap to Projected Revenue|Market Cap to Future Revenue Ratio FRES|Market Cap to Future Revenue Ratio GTG Labs (GENE)|ME (23andme.com) - Forward P/S Multiple|Forward P/S Multiple Psychemedics Inc